Friday morning and afternoon, officials conducted a deliberate — and sometimes difficult — serious mental illness hearing for ...

and depression, according to a longitudinal study published in JAMA Psychiatry in 2022. Medications used to treat these conditions can sometimes trigger a manic episode, particularly if there is a ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

Existing drugs for manic depression - such as loxapine, promazine and haloperidol - can cause weight gain and a feeling of tiredness and lethargy. They have also been inconsistent at preventing ...